A Global, Phase 3, Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 Mg (Triptorelin Mesylate Injection, 22.5 Mg) in Patients with Advanced Prostate Cancer (KATANA E6M)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Triptorelin (Primary)
Indications Carcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms KATANA E6M
Sponsors Foresee Pharmaceuticals

Most Recent Events

10 Feb 2025 According to Foresee Pharmaceuticals media release, data from this trial will presented at American Society of Clinical Oncology, Genitourinary (ASCO-GU) Cancers Symposium conference
04 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight